
-
Gaza rescuers say 23 killed in Israel strike on residential block
-
'Catastrophe': Volkswagen town rattled by Trump trade war
-
Premier League claims fifth Champions League spot
-
Race to save Sweden's 17th century warship in preservation project
-
Russia demands France explain detention of government employee
-
Equities, oil plunge as US, China crank up trade war
-
Greek general strike hits transport and commerce
-
How the EU is responding to Trump's trade assault
-
'Terrifying' French film abuses report prompts calls for change
-
Beijing consumers mull spending habits as tariffs kick in
-
Trump's steep tariffs trigger fresh market panic
-
India readies for US extradition of Mumbai attacks suspect
-
Thailand revokes visa of US academic charged with royal insult
-
Voeller extends Germany role until Euro 2028
-
Villa's Emiliano Martinez winds up PSG with cap
-
Hostage families fear outcome of intense Israeli strikes on Gaza
-
China seeks to 'tariff-proof' economy as trade war with US deepens
-
Some US consumers in 'survival mode' as Trump tariffs arrive
-
Japan to sell more rice reserves as prices soar
-
US takes aim at Zuckerberg's social media kingdom
-
US Pentagon chief says will not let China 'threaten' Panama Canal
-
Vietnam, Spain pledge to upgrade ties after tariff shock
-
'Some innings': Arya's 39-ball ton thrusts him into IPL spotlight
-
India central bank cuts interest rates as Trump tariffs kick in
-
Taiwan exporters count the cost of Trump's 'ridiculous' tariffs
-
Injury-time goal gives Brazil first win over US women since 2014
-
Japan badminton ace Shida blasts 'stalker' Chinese fans
-
Ekitike has Frankfurt dreaming of Europa League repeat
-
Trump's new tariffs take effect, with 104% on Chinese goods
-
Shai scores 42, Doncic ejected as Thunder down Lakers
-
Nepal royalists seek return of king
-
Man Utd reliant on Europa League with season on life support
-
Kim Jong Un's sister says North Korea denuclearisation is a 'daydream'
-
Trump tariffs leave Italy's luxury furniture makers sitting uncomfortably
-
EU plan to end Russian fertiliser imports unsettles farmers
-
Equities resume selloff as Trump cranks up trade war
-
Inside Europe's last 'open-outcry' trading floor
-
Trumps presses on with 104% tariffs on China
-
AI tool aims to help conserve Japan's cherry trees
-
The Metals Company courts Trump for deep-sea mining contract
-
Indonesia president says ready to temporarily shelter Gazans
-
Musk brands Trump aide 'dumber than a sack of bricks' in tariff spat
-
Author of explosive Meta memoir to star at US Senate hearing
-
UK to host Europe's first Universal theme park
-
'It's beautiful': Arteta hails Rice free-kick magic as Arsenal stun Real
-
Argentine Congress backs inquiry into Milei crypto scandal
-
US will not let China disrupt Panama Canal: Pentagon chief
-
Judge orders White House to restore AP access
-
Shaken Real Madrid insist Arsenal comeback possible
-
Bayern 'fully believe' despite Inter setback, says Kompany

Moderna sues Pfizer, BioNTech over Covid vaccine
Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.
The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease.
"Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement.
"Pfizer and BioNTech copied this technology, without Moderna's permission, to make Comirnaty," Moderna alleged.
Pfizer and BioNTech said they were aware of the litigation, and each issued statements denying any wrongdoing.
"BioNTech's work is original, and we will vigorously defend against all allegations of patent infringement," the firm said, adding it "respects valid and enforceable intellectual property rights of others."
Pfizer pledged to "vigorously defend against the allegations of the lawsuit."
The mRNA technology used in the Moderna and Pfizer-BioNTech shots differs from that in traditional vaccines, which rely on injecting weakened or dead forms of a virus to allow the immune system to recognize it and build antibodies.
Instead, mRNA vaccines deliver instructions to cells to build a harmless piece of the spike protein found on the surface of the virus that causes Covid-19.
After creating this spike protein, cells can recognize and fight the real virus, hailed as a major advancement in development of vaccines.
- Key tool against deadly pandemic -
The shots have repeatedly been the subject of inaccurate claims that they are dangerous, but health authorities say they are safe and effective.
The lawsuits -- in US district court in Massachusetts, and in regional court in Dusseldorf, Germany -- are not seeking the removal of the rival vaccine or an injunction on future sales.
Moderna said it had begun building up the technology in 2010 and patented work on corona viruses in 2015 and 2016, which allowed for rollout of its shots in "record time" after the pandemic struck.
The virus has killed at least 6.48 million people worldwide since 2020 and made nearly 600 million ill, according to a Johns Hopkins University tracker.
In addition to death and suffering, the disease has led to a re-shaping of life ranging from a change in norms on working from home to a scrambling of supply chains and workforces.
Moderna said it pledged in October 2020 not to enforce its Covid-19-related patents while the pandemic continued, but less than two years later changed that stance as the fight shifted gears.
"Moderna expected companies such as Pfizer and BioNTech to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets," it said.
"Pfizer and BioNTech have failed to do so," the firm added.
These types of lawsuits are not unheard of in the pharmaceutical industry, where patents can be worth billions of dollars, and can take years to resolve.
"It is an unfortunate but rather regular occurrence that other companies make allegations that a successful product potentially infringes their intellectual property rights," BioNTech said in a statement.
O.Lorenz--BTB